CU24560B1 - N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio - Google Patents

N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio

Info

Publication number
CU24560B1
CU24560B1 CU2019000066A CU20190066A CU24560B1 CU 24560 B1 CU24560 B1 CU 24560B1 CU 2019000066 A CU2019000066 A CU 2019000066A CU 20190066 A CU20190066 A CU 20190066A CU 24560 B1 CU24560 B1 CU 24560B1
Authority
CU
Cuba
Prior art keywords
difluorocyclohexyl
pyrazol
methyl
morfolinopirimidin
modulator
Prior art date
Application number
CU2019000066A
Other languages
English (en)
Other versions
CU20190066A7 (es
Inventor
Dipak Amrutkar
Kelly Foster
Thomas Jacobsen
Martin JEFSON
Gregg Keaney
Janus Larsen
Karin Nielsen
Original Assignee
Cadent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadent Therapeutics Inc filed Critical Cadent Therapeutics Inc
Publication of CU20190066A7 publication Critical patent/CU20190066A7/es
Publication of CU24560B1 publication Critical patent/CU24560B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)

Abstract

<p>Se revela el compuesto N-(4,4-difluorociclohexil)-2-(3-metil-1H-pirazol-1-il)-6-morfolinopirimidin-4-amina</p> <p>ESPACIO PARA FÓRMULA</p> <p>útiles para tratar una variedad de enfermedades, trastornos o condiciones, asociados con canales de potasio.</p>
CU2019000066A 2017-01-23 2018-01-23 N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio CU24560B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449270P 2017-01-23 2017-01-23
PCT/US2018/014792 WO2018136917A1 (en) 2017-01-23 2018-01-23 Potassium channel modulators

Publications (2)

Publication Number Publication Date
CU20190066A7 CU20190066A7 (es) 2020-03-04
CU24560B1 true CU24560B1 (es) 2021-12-08

Family

ID=61188924

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000066A CU24560B1 (es) 2017-01-23 2018-01-23 N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio

Country Status (29)

Country Link
US (4) US9975886B1 (es)
EP (1) EP3571193B1 (es)
JP (1) JP6997197B2 (es)
KR (1) KR102664772B1 (es)
CN (1) CN110198935B (es)
AR (1) AR110770A1 (es)
BR (1) BR112019014814B1 (es)
CL (1) CL2019002031A1 (es)
CO (1) CO2019009060A2 (es)
CU (1) CU24560B1 (es)
DK (1) DK3571193T3 (es)
EA (1) EA036668B1 (es)
ES (1) ES2906078T3 (es)
HR (1) HRP20220079T1 (es)
HU (1) HUE057710T2 (es)
IL (1) IL267954B (es)
LT (1) LT3571193T (es)
MX (1) MX2019008682A (es)
MY (1) MY195123A (es)
PH (1) PH12019501678A1 (es)
PL (1) PL3571193T3 (es)
PT (1) PT3571193T (es)
RS (1) RS62899B1 (es)
SG (1) SG11201905893WA (es)
SI (1) SI3571193T1 (es)
TW (1) TWI751271B (es)
UA (1) UA123810C2 (es)
WO (1) WO2018136917A1 (es)
ZA (1) ZA201904458B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017275657B2 (en) * 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
BR112019014814B1 (pt) * 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
CA3116339A1 (en) * 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6059883B2 (ja) 1978-05-08 1985-12-27 北興化学工業株式会社 農園芸用殺菌剤
GB2183243B (en) 1985-10-09 1990-01-24 Nippon Oil Co Ltd Process for preparing oil-soluble nitrogen-containing compounds
WO1989011279A1 (en) 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
LU87304A1 (fr) 1988-07-29 1990-02-07 Oreal Nouveaux derives d'ureylene triamino-2,4,6 pyrimidine oxyde-3,leur preparation et leur utilisation en cosmetique et dermopharmacie
JPH02282251A (ja) 1989-04-24 1990-11-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE4034762A1 (de) 1990-11-02 1992-05-07 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
HU209678B (en) 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
DK72693D0 (da) 1993-06-18 1993-06-18 Lundbeck & Co As H Compounds
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
WO1998006709A1 (en) 1996-08-14 1998-02-19 Takeda Chemical Industries, Ltd. Cyclic urea compounds, their production and use as herbicides
DE19642863A1 (de) 1996-10-17 1998-04-23 Bayer Ag Amide
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
JPH11282132A (ja) 1998-03-27 1999-10-15 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JP2000072695A (ja) 1998-08-24 2000-03-07 Sumitomo Pharmaceut Co Ltd 環状化合物
JP2000075449A (ja) 1998-08-31 2000-03-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の現像方法
US6878712B1 (en) 1999-09-04 2005-04-12 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
EP1218003A4 (en) 1999-09-13 2004-02-11 David M Swope COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
AU7388701A (en) 2000-06-29 2002-01-08 Neurosearch As Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
CA2425259A1 (en) 2000-10-11 2002-04-18 Tularik, Inc. Modulation of ccr4 function
AU2002239508B9 (en) 2000-12-07 2005-09-08 Gilead Palo Alto, Inc. Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
CA2434152A1 (en) 2001-01-16 2002-07-18 Astrazeneca Ab Therapeutic heterocyclic compounds
IL156602A0 (en) 2001-01-16 2004-01-04 Astrazeneca Ab Therapeutic chromone compounds
JP4280068B2 (ja) 2001-01-16 2009-06-17 アストラゼネカ・アクチエボラーグ 治療用クロマン化合物
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
NZ529043A (en) * 2001-04-16 2006-11-30 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
AU2003258630A1 (en) 2002-08-19 2004-03-11 Glaxo Group Limited Pyrimidine derivatives as selective cox-2 inhibitors
JP2005536554A (ja) 2002-08-23 2005-12-02 ユニバーシティ オブ コネチカット 新規なビフェニル及びビフェニル様カンナビノイド
GB0311201D0 (en) 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
US7589092B2 (en) 2003-06-20 2009-09-15 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
CN1867560A (zh) 2003-08-13 2006-11-22 武田药品工株式会社 4－嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
JP4948173B2 (ja) 2003-10-10 2012-06-06 ニツポネツクス・インコーポレーテツド 過剰増殖性疾患治療用ピリミジン誘導体
AU2004282189B2 (en) 2003-10-17 2011-11-17 Incyte Holdings Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
CN100554264C (zh) 2003-11-24 2009-10-28 弗·哈夫曼-拉罗切有限公司 吡唑基与咪唑基嘧啶
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
NZ549673A (en) 2004-03-30 2010-03-26 Taisho Pharmaceutical Co Ltd Pyrimidine derivatives and methods of treatment related to the use thereof
JP4926943B2 (ja) 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
AU2005286593A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
GB0422556D0 (en) 2004-10-11 2004-11-10 Syngenta Participations Ag Novel insecticides
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
WO2006065590A2 (en) 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
BRPI0519774A2 (pt) 2005-01-19 2009-02-10 Biolipox Ab composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto
JP2008527030A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
US20090069384A1 (en) 2005-01-19 2009-03-12 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
WO2006077365A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
EP1844013A1 (en) 2005-01-19 2007-10-17 Biolipox AB Indoles useful in the treatment of inflammation
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
CN101115736A (zh) * 2005-03-14 2008-01-30 神经研究公司 钾通道调节剂和它们的医药用途
AU2006224605B2 (en) 2005-03-14 2012-03-01 Aniona Aps Potassium channel modulating agents and their medical use
US20060156481A1 (en) 2005-03-22 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP2008534472A (ja) * 2005-03-22 2008-08-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
DE602006018456D1 (de) 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
US20080280906A1 (en) 2005-07-30 2008-11-13 David Andrews Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders
DE102005043165A1 (de) 2005-09-12 2007-03-22 Merck Patent Gmbh Metallkomplexe
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
FR2892859B1 (fr) 2005-10-27 2008-06-06 Commissariat Energie Atomique Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications
US8642278B2 (en) 2005-11-22 2014-02-04 University Of South Florida Inhibition of cell proliferation
RU2008128452A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
WO2007070600A2 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
WO2007071632A2 (en) 2005-12-20 2007-06-28 Neurosearch A/S 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
CN101426926A (zh) 2006-03-13 2009-05-06 珀金埃尔默Las公司 用于质谱法检测的底物和内标
JP2009535370A (ja) 2006-05-02 2009-10-01 クリス ルントフェルト ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤
WO2008005538A2 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
JP2009545588A (ja) 2006-08-03 2009-12-24 プロセンサ テクノロジーズ ビー．ブイ． 抗生物質組成物
WO2008028935A2 (en) 2006-09-07 2008-03-13 Neurosearch A/S Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
MX2009003142A (es) 2006-10-03 2009-04-06 Neurosearch As Derivados de indazolilo utiles como agentes moduladores del canal de potasio.
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
WO2008064218A2 (en) 2006-11-21 2008-05-29 Smithkline Beecham Corporation Amido anti-viral compounds
US20100234341A1 (en) 2006-12-04 2010-09-16 Marion Lanier Substituted pyrimidines as adenosine receptor antagonists
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
WO2008098058A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
US8940900B2 (en) 2007-02-28 2015-01-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2008110891A2 (en) 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
MX2009010122A (es) 2007-03-28 2009-10-19 Neurosearch As Derivados de purinilo y su uso como moduladores del canal de potasio.
BRPI0808746B8 (pt) 2007-03-28 2021-05-25 Neurosearch As derivado de purinila como modulador do canal de potássio, composição farmacêutica, e, uso de um derivado de purinila.
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
JP5111039B2 (ja) 2007-09-27 2012-12-26 富士フイルム株式会社 重合性化合物、重合開始剤、および染料を含有する光硬化性組成物
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
RU2434634C1 (ru) 2008-02-08 2011-11-27 Шисейдо Компани Лтд. Отбеливающий агент и композиция для кожи для наружного применения
CA2717110A1 (en) 2008-02-28 2009-09-03 Saint Mary's University Compounds, complexes and uses thereof
US20110053907A1 (en) 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
WO2009125870A1 (en) 2008-04-09 2009-10-15 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
EP2279192B1 (en) 2008-05-28 2013-10-30 Merck Patent GmbH Ionic liquids
WO2009150462A1 (en) 2008-06-11 2009-12-17 Astrazeneca Ab Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CN102177154A (zh) * 2008-09-02 2011-09-07 神经研究公司 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用
CN101684098A (zh) 2008-09-24 2010-03-31 中国科学院上海药物研究所 一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用
WO2010034707A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
AR074870A1 (es) 2008-12-24 2011-02-16 Palau Pharma Sa Derivados de pirazolo (1,5-a ) piridina
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
WO2010151797A2 (en) 2009-06-26 2010-12-29 University Of Massachusetts Compounds for modulating rna binding proteins and uses therefor
RS54718B1 (en) 2009-07-08 2016-08-31 Baltic Bio Ab 1,2,4-THIAZOLIDIN-3-DERIVATIVES AND THEIR USE IN CANCER TREATMENT
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
TW201111379A (en) 2009-09-09 2011-04-01 Vifor Int Ag Novel thiazole-and oxazole-hepcidine-antagonists
EP2499195B1 (en) 2009-11-13 2020-12-09 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
AT509266B1 (de) 2009-12-28 2014-07-15 Tech Universität Wien Substituierte pyridine und pyrimidine
EP2542081A4 (en) 2010-03-01 2013-07-31 Gtx Inc COMPOSITIONS FOR CANCER TREATMENT
AU2011253057B2 (en) 2010-05-13 2014-11-20 Amgen Inc. Nitrogen heterocyclic compounds useful as PDE10 inhibitors
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
BR112013003815A2 (pt) 2010-08-20 2019-09-24 Gruenenthal Chemie derivados de carboxamida cílicos substituódos e derivados de ureia como ligantes do receptor vaniloide
WO2012025239A1 (en) * 2010-08-27 2012-03-01 Grünenthal GmbH Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
EP2622676A1 (en) 2010-09-30 2013-08-07 Basf Se Additive for electrolytes
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
CN104906103B (zh) 2010-12-14 2018-05-18 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
WO2012109343A2 (en) 2011-02-08 2012-08-16 President And Fellows Of Harvard College Iron complexes and methods for polymerization
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102731492B (zh) 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
LT2707101T (lt) 2011-05-12 2019-05-27 Proteostasis Therapeutics, Inc. Proteostazę reguliuojantys agentai
WO2012163489A1 (en) 2011-05-31 2012-12-06 Merck Patent Gmbh Compounds containing hydrido-tricyano-borate anions
US9073801B2 (en) 2011-06-03 2015-07-07 Massachusetts Institute Of Technology Z-selective ring-closing metathesis reactions
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
EP2750505A4 (en) 2011-08-29 2015-08-05 Ptc Therapeutics Inc ANTIBACTERIAL COMPOUNDS AND METHODS FOR THEIR USE
JP5741850B2 (ja) 2011-09-13 2015-07-01 コニカミノルタ株式会社 光学フィルム、それを含む偏光板および液晶表示装置
JP5857713B2 (ja) 2011-12-15 2016-02-10 コニカミノルタ株式会社 光学フィルム、偏光板、及び液晶表示装置
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
FR2992317B1 (fr) 2012-06-22 2016-05-13 Diverchim Procede de preparation de peptides chiraux
CA2880299A1 (en) 2012-07-27 2014-01-30 Bial - Portela & Ca, S.A. Process for the synthesis of substituted urea compounds
US20150246024A1 (en) 2012-08-20 2015-09-03 The University Of Chicago Methods and compositions for inhibiting gram positive bacteria
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
BR112015006029B1 (pt) 2012-09-18 2022-01-25 Heptares Therapeutics Limited Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
US9605078B2 (en) 2012-11-16 2017-03-28 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
ES2469290B2 (es) 2012-12-17 2015-01-26 Ocupharm Diagnostics S.L. Mejora en la aplicación tópica de fármacos oculares mediante la administración de nucleótidos
US9499762B2 (en) 2012-12-21 2016-11-22 Afton Chemical Corporation Additive compositions with a friction modifier and a detergent
US9279094B2 (en) 2012-12-21 2016-03-08 Afton Chemical Corporation Friction modifiers for use in lubricating oil compositions
CA2914178C (en) 2013-01-07 2023-06-13 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2014108487A1 (en) 2013-01-10 2014-07-17 Universite D'aix-Marseille P-stereogenic chiral precursor of chiral ligands and use thereof
US9487472B2 (en) 2013-02-26 2016-11-08 President And Fellows Of Harvard College Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
JP2016520552A (ja) 2013-04-05 2016-07-14 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｐｐａｒアゴニスト
US20160155959A1 (en) 2013-07-02 2016-06-02 Merck Patent Gmbh Organic Electroluminescent Device
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP2016529241A (ja) 2013-07-25 2016-09-23 フォンダッツィオーネ・テレソン Ｆａｐｐ２阻害剤及びそれらの使用
WO2015013715A2 (en) 2013-07-26 2015-01-29 Thr Regents Of The University Of California C-h fluorination of heterocycles with silver (ii) fluoride
WO2015031725A1 (en) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Transition metal-catalyzed imidation of arenes
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
SI3060550T1 (sl) 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilne spojine kot inhibitorji BTK in uporabe le-teh
WO2015069752A1 (en) 2013-11-05 2015-05-14 The Regents Of The University Of California Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using
CN103626741A (zh) 2013-11-26 2014-03-12 苏州大学 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物
PL3527639T3 (pl) 2013-11-29 2022-03-07 Proionic Gmbh Sposób łączenia tworzywa termoplastycznego za pomocą promieniowania mikrofalowego
WO2015084936A1 (en) 2013-12-04 2015-06-11 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
CA2944669A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
GB201502412D0 (en) 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
US20170299609A1 (en) 2016-04-18 2017-10-19 Wright State University Treatment of amyotrophic lateral sclerosis with sk channel activators
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
BR112019014814B1 (pt) 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
WO2018136918A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels

Also Published As

Publication number Publication date
IL267954B (en) 2022-02-01
HUE057710T2 (hu) 2022-05-28
BR112019014814B1 (pt) 2024-03-12
PT3571193T (pt) 2022-03-25
PL3571193T3 (pl) 2022-04-25
BR112019014814A2 (pt) 2020-02-27
HRP20220079T1 (hr) 2022-04-15
JP2020504165A (ja) 2020-02-06
KR20190110572A (ko) 2019-09-30
CN110198935B (zh) 2022-05-31
PH12019501678A1 (en) 2020-06-01
RS62899B1 (sr) 2022-03-31
UA123810C2 (uk) 2021-06-02
CL2019002031A1 (es) 2019-10-04
ZA201904458B (en) 2023-04-26
US10717728B2 (en) 2020-07-21
CN110198935A (zh) 2019-09-03
AR110770A1 (es) 2019-05-02
US10351553B2 (en) 2019-07-16
CU20190066A7 (es) 2020-03-04
CO2019009060A2 (es) 2019-08-30
EP3571193A1 (en) 2019-11-27
EP3571193B1 (en) 2021-12-01
MY195123A (en) 2023-01-11
SG11201905893WA (en) 2019-08-27
ES2906078T3 (es) 2022-04-13
EA036668B1 (ru) 2020-12-07
US20180215746A1 (en) 2018-08-02
KR102664772B1 (ko) 2024-05-10
TWI751271B (zh) 2022-01-01
US9975886B1 (en) 2018-05-22
SI3571193T1 (sl) 2022-04-29
MX2019008682A (es) 2019-09-18
WO2018136917A1 (en) 2018-07-26
TW201838985A (zh) 2018-11-01
EA201991488A1 (ru) 2019-12-30
IL267954A (en) 2019-09-26
US20210380571A1 (en) 2021-12-09
DK3571193T3 (da) 2022-01-17
LT3571193T (lt) 2022-02-10
US20190352293A1 (en) 2019-11-21
JP6997197B2 (ja) 2022-01-17

Similar Documents

Publication Publication Date Title
EA201891211A1 (ru) Ингибиторы cxcr2
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
ECSP17083426A (es) PROCESOS E INTERMEDIARIOS PARA LA PREPARACIÓN DE {1-(ETILSULFONIL)-3-[4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL]AZETIDIN-3-IL}ACETONITRILO
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
AR112276A1 (es) Polimorfos de 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
UY37706A (es) Compuestos antitumorales
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201791530A1 (ru) НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ
CU24560B1 (es) N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio
CL2017000151A1 (es) Derivados de piridona
EA201991655A1 (ru) Тиобензоимидазолы в качестве фунгицидов
AR109407A1 (es) Compuesto de 1-acetil-3-fenilurea y su uso
AR109406A1 (es) Compuesto de 1-fenil-3-carbamoilurea y su uso
AR109409A1 (es) Compuesto de 3-piridiloxifenildihidrouracilo y su uso
AR109405A1 (es) Compuestos de fenilurea y su uso
AR125853A2 (es) Composición farmacéutica de una sal hemisulfato de un compuesto nucleotídico
UA127754U (uk) Поліетергуанідингідрохлорид як бактерицидна речовина
RU2014130710A (ru) Стимулятор роста яровой пшеницы
UA145103U (uk) Застосування еторикоксибу як фригопротекторного засобу